Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children

A Phase 3, Open-Label Trial, Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Healthy Children Previously Partially Immunized With Prevenar

The purposes of this study are to evaluate the safety of 13-valent pneumococcal Conjugate Vaccine (13vPnC) in children who have already been vaccinated with Prevenar. The study will also assess the immunological response (measure the amount of antibodies, i.e. proteins that fight off germs) produced by children after they have been given the 13-valent pneumococcal vaccine at 5 and 12 months or 12 months of age. In addition, reactions at the injection site will be assessed during the study.

Inclusion Criteria:

• Healthy children previously immunized with 1 or 2 doses of Prevenar.
• Group 1: Male or female subjects between the age of >=140 and <=196 days of age at time of enrollment.
• Group 2: Male or female subjects between the age of >=336 and <=392 days of age at time of enrollment
• Available for entire study period.

Exclusion Criteria:

• Previous reaction or contra-indication to pneumococcal vaccine or vaccine related component.
• Previous vaccination with licensed or investigational pneumococcal vaccine other than Prevenar.